127 related articles for article (PubMed ID: 35339914)
1. Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation.
Faskhoudi MA; Molaei P; Sadrkhanloo M; Orouei S; Hashemi M; Bokaie S; Rashidi M; Entezari M; Zarrabi A; Hushmandi K; Mirzaei S; Gholami MH
Pathol Res Pract; 2022 May; 233():153851. PubMed ID: 35339914
[TBL] [Abstract][Full Text] [Related]
2. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
3. ANP32B inhibition suppresses the growth of prostate cancer cells by regulating c-Myc signaling.
Zhou C; Ma H; Yu W; Zhou Y; Zhang X; Meng Y; Chen C; Zhang J; Shi G
Biochem Biophys Res Commun; 2024 Feb; 698():149543. PubMed ID: 38266312
[TBL] [Abstract][Full Text] [Related]
4. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.
Hahm ER; Singh KB; Singh SV
Cell Cycle; 2016 Sep; 15(17):2309-20. PubMed ID: 27341160
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.
Akinyeke TO; Stewart LV
Cancer Biol Ther; 2011 Jun; 11(12):1046-58. PubMed ID: 21525782
[TBL] [Abstract][Full Text] [Related]
6. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
Yan Y; Zhou B; Qian C; Vasquez A; Kamra M; Chatterjee A; Lee YJ; Yuan X; Ellis L; Di Vizio D; Posadas EM; Kyprianou N; Knudsen BS; Shah K; Murali R; Gertych A; You S; Freeman MR; Yang W
Nat Commun; 2022 Feb; 13(1):669. PubMed ID: 35115556
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
8. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells.
Rohan JN; Weigel NL
Endocrinology; 2009 May; 150(5):2046-54. PubMed ID: 19164469
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.
Pan H; Zhu Y; Wei W; Shao S; Rui X
World J Surg Oncol; 2018 Mar; 16(1):59. PubMed ID: 29554906
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.
Wang J; Yang X; Li R; Wang L; Gu Y; Zhao Y; Huang KH; Cheng T; Yuan Y; Gao S
Oncol Rep; 2018 Nov; 40(5):2814-2825. PubMed ID: 30132573
[TBL] [Abstract][Full Text] [Related]
12. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway.
Quan Y; Wang N; Chen Q; Xu J; Cheng W; Di M; Xia W; Gao WQ
Oncotarget; 2015 Sep; 6(28):26494-507. PubMed ID: 26317998
[TBL] [Abstract][Full Text] [Related]
13. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
14. miR-296-3p Negatively Regulated by Nicotine Stimulates Cytoplasmic Translocation of c-Myc via MK2 to Suppress Chemotherapy Resistance.
Deng X; Liu Z; Liu X; Fu Q; Deng T; Lu J; Liu Y; Liang Z; Jiang Q; Cheng C; Fang W
Mol Ther; 2018 Apr; 26(4):1066-1081. PubMed ID: 29525743
[TBL] [Abstract][Full Text] [Related]
15. MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer.
Qiu J; Yang B
Mol Cell Biochem; 2021 Jan; 476(1):1-10. PubMed ID: 32935296
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling.
Bhatia V; Mula RV; Weigel NL; Falzon M
Mol Cancer Res; 2009 Jul; 7(7):1119-31. PubMed ID: 19584267
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cell survival and proliferation by nimbolide in human androgen-independent prostate cancer (PC-3) cells: involvement of the PI3K/Akt pathway.
Raja Singh P; Sugantha Priya E; Balakrishnan S; Arunkumar R; Sharmila G; Rajalakshmi M; Arunakaran J
Mol Cell Biochem; 2017 Mar; 427(1-2):69-79. PubMed ID: 28025797
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway.
Qiao X; Lv SX; Qiao Y; Li QP; Ye B; Wang CC; Miao L
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8630-8639. PubMed ID: 30575903
[TBL] [Abstract][Full Text] [Related]
20. HUWE1 upregulation has tumor suppressive effect in human prostate cancer cell lines through c-Myc.
Qu H; Liu H; Jin Y; Cui Z; Han G
Biomed Pharmacother; 2018 Oct; 106():309-315. PubMed ID: 29966975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
